
Transfusion Related Acute Lung Injury (TRALI)
Pathophysiology
This is sometimes referred to as non-cardiogenic pulmonary oedema, or pulmonary type transfusion reaction. Most commonly, it is due to donor white cell (granulocyte) antibodies reacting with patient leucocytes. Less commonly, the leucocyte antibodies are present in the patient and react with the granulocytes in the transfused unit, usually only with granulocyte transfusions. With both mechanisms, large quantities of leucocyte aggregates are formed, and become trapped in the pulmonary capillaries with subsequent leucocyte and complement activation and immune response. It is more commonly associated with blood products with high plasma content (platelets and FFP).
TRALI is more common in unwell/hospitalised patients. Its incidence has reduced with the use of FFP from male donors only.
Clinical Signs
- Acute respiratory insufficiency in the setting of non-cardiogenic pulmonary oedema, usually within 1 to 2 hours after transfusion, but may be delayed up to 4 hours.
- Dyspnoea, tachypnoea, hypoxia with or without fever, and hypotension are present.
- Chest X-ray shows "bat wing" central distribution of pulmonary congestion.
Laboratory Diagnosis and Evaluation
Standard transfusion reaction investigations are negative. A common differential diagnosis is Transfusion-associated circulatory overload (TACO). The table below might help differentiate between the two respiratory-type reactions.

Reference
C Hillis, A Shih, N Heddle. (2016). Best practices in the differential diagnosis and reporting of acute transfusion reactions. International Journal of Clinical Transfusion Medicine. 4(1–14).
Management
- Stop transfusion.
- Supplement oxygen. 70% require intubation for average of 40 hours. Pulmonary infiltrates. Respiratory insufficiency usually resolves within 48-96 hours and recovery is complete. Mortality 5%.
- Notify Blood Bank of suspected mechanisms so that the donor can be investigated and prevented from donating again.
- If related to granulocyte infusion, future transfusions should be HLA compatible.
- If the patient has leucoagglutinins, discuss with the Transfusion Medicine Specialist.
Topic Code: 5118